European Study Evaluating the EMBLOK Embolic Protection System During TAVR
European Study Evaluating the EMBLOK Cerebral Embolic Protection System During Transcatheter Aortic Valve Replacement (TAVR)
Sponsor: Emblok, Inc.
This NA trial investigates Aortic Valve Disease and is currently completed. Emblok, Inc. leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2024 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jun 2023 — Apr 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 9 earlier versions
-
Jun 2021 — Jun 2023 [monthly]
Recruiting NA
-
Feb 2021 — Jun 2021 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Aug 2020 — Jan 2021 [monthly]
Recruiting NA
-
Mar 2020 — Aug 2020 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
-
Sep 2018 — Mar 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting NA
-
Mar 2018 — Jun 2018 [monthly]
Recruiting NA
-
May 2017 — Mar 2018 [monthly]
Recruiting NA
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emblok, Inc.
- Meditrial Europe Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .